For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | - | 147,292 | 131,096 | 208,021 |
| Reclassification of unrealized loss on short-term investments to other expense, net | 0 | 0* | 0 | 0 |
| Acquired in-process research and development | - | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 |
| General and administrative | 62,594 | 77,633 | 103,115 | 360,416 |
| Total operating expenses | 195,212 | 224,925 | 234,211 | 568,437 |
| Other income, net | 5,788 | 5,753 | 2,418 | 2,729 |
| Net loss | -189,424 | -219,172 | -231,793 | -565,708 |
| Reclassification of cumulative currency translation gain to other income, net | - | 0* | - | - |
| Foreign currency translation adjustments | 84 | -36 | 43 | -189 |
| Unrealized gain (loss) on short-term investments | -176 | 205 | 0 | 0 |
| Comprehensive loss | -189,516 | -219,003 | -231,750 | -565,897 |
| Basic EPS | -0.24 | -0.286 | -0.31 | -0.76 |
| Diluted EPS | -0.24 | -0.286 | -0.31 | -0.76 |
| Basic Average Shares | 775,458,141 | 766,702,133 | 743,415,917 | 742,615,007 |
| Diluted Average Shares | 775,458,141 | 766,702,133 | 743,415,917 | 742,615,007 |
Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT)